In a recent research report, financial services company Stifel Nicolaus has lowered its price objective for Illumina (NASDAQ:ILMN) from $225.00 to $200.00. This downward adjustment suggests a potential upside of 51.11% from the company’s previous close.
Shares of NASDAQ:ILMN opened at $132.35 on Friday, reflecting a decrease in value compared to its 52-week high of $248.87 and its 52-week low of $127.37. Illumina has a market capitalization of $20.95 billion and operates with a price-to-earnings ratio of -4.97, a PEG ratio of 7.20, and a beta of 1.12.
The company’s quick ratio stands at 1.13, indicating its ability to meet short-term obligations, while the current ratio is 1.40, highlighting its ability to cover current liabilities with current assets. Additionally, it maintains a debt-to-equity ratio of 0.23.
Illumina currently boasts a 50-day moving average price of $165.38 and a 200-day moving average price of $192.62.
With regards to institutional investors’ involvement in the stock, Bouvel Investment Partners LLC raised its position in Illumina by 2.9% during the first quarter, owning now 4,325 shares valued at approximately $1,006,000 after purchasing an additional 120 shares during that period.
Vestmark Advisory Solutions Inc., on the other hand, saw an increase in their stake by acquiring an additional 330 shares during the first quarter and now owns 7,662 shares worth around $1,782,000.
Mn Services Vermogensbeheer B.V., also increased their position through the purchase of an additional 2,400 shares in the last quarter; they currently hold 77,400 shares worth about $17,999,000.
Harvest Fund Management Co. Ltd experienced a significant growth in their holdings by acquiring an additional 192 shares during the first quarter, resulting in a total of 413 shares now valued at approximately $96,000.
Lastly, Ellevest Inc. increased its position by 19.4% during the first quarter through the acquisition of an additional 131 shares. They currently hold 806 shares worth around $187,000.
In terms of ownership distribution, hedge funds and other institutional investors control approximately 92.17% of Illumina’s stock.
Looking back at Illumina’s recent earnings results announced on August 9th, the company reported earnings per share (EPS) of $0.32 for the quarter, surpassing the consensus estimate of $0.02 by $0.30. The firm generated revenue amounting to $1.18 billion for the quarter compared to analyst predictions of $1.16 billion.
Illumina showcased a positive return on equity of 1.97% and a negative net margin of 93.86%. Moreover, its quarterly revenue saw a growth rate of 1.2% when compared to the same period last year while it earned $0.57 in earnings per share during that time frame.
Equity analysts project that Illumina will report an EPS of 0.83 for the current year.
In conclusion, Stifel Nicolaus’ revised price objective has set a potential upside target for Illumina at $200.00 following its recent share price decrease to $132.35 as reported on September 30, 2023.
[bs_slider_forecast ticker=”FSLR”]
Uncertainties Surrounding Illumina’s Performance Amidst Target Price Drops and Mixed Analyst Ratings
September 30, 2023 – Illumina faces a series of target price drops and mixed ratings from analysts, as revealed in recent reports. Canaccord Genuity Group has reduced its target price for Illumina from $300.00 to $285.00 and maintained a “buy” rating on the stock in a report dated August 16th, adding to the perplexity surrounding the company’s performance.
Similarly, Credit Suisse Group lowered its target price on Illumina from $225.00 to $200.00 and assigned a “neutral” rating on the stock in a report released on August 10th. Bank of America also decreased their price objective from $230.00 to $210.00 in a report published the same day, further raising concerns about Illumina’s future prospects.
Adding to the intricate tapestry of opinions is Sanford C. Bernstein, which recently initiated coverage on Illumina with an “underperform” rating and set a price objective of $111.00 on the stock. This analysis portrayed a rather bearish outlook for the company amidst lingering uncertainties.
UBS Group chimed in by revising down their price objective from $240.00 to $230.00 and maintaining a “neutral” rating on Illumina in another report released on August 8th, adding more complexities to the overall perception of the company’s financial health.
With three investment analysts issuing sell ratings, seven giving hold ratings, and eight endorsing buy ratings, there seems to be no consensus regarding Illumina’s future trajectory at present. In fact, Bloomberg indicates that according to its data compilation method, there is presently a prevailing consensus rating of “Hold” for Illumina with an accompanying consensus target price of approximately $222.85.
In recent news related to insider trading activities within Illumina, it has been reported that Senior Vice President Susan H. Tousi sold 500 shares of the company’s stock on August 22nd. The average price of the shares sold was $167.04, resulting in a total transaction value of $83,520.00. This disclosure was made in a filing with the Securities and Exchange Commission (SEC) and can be accessed through the corresponding link. As a consequence of this transaction, Tousi now holds 45,524 shares in Illumina, valued at $7,604,328.96.
Metrics such as these can shed light on the mindset of company insiders and their outlook on Illumina’s performance. Currently, company insiders own approximately 0.13% of the stock.
Amidst the complexities posed by varying target prices, ratings from analysts and recent insider trading activities, it is evident that Illumina finds itself amidst an environment brimming with uncertainties. Investors should diligently consider these factors while making informed decisions regarding their involvement in this particular market arena.
